Cargando…

Atrial fibrillation in COVID-19 patients receiving remdesivir, matched case-control analysis

Detalles Bibliográficos
Autores principales:	Bistrovic, Petra, Manola, Sime, Papic, Ivan, Jordan, Ana, Ortner Hadziabdic, Maja, Lucijanic, Marko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Inc. 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9085444/ https://www.ncbi.nlm.nih.gov/pubmed/35577624 http://dx.doi.org/10.1016/j.ajem.2022.04.051

Ejemplares similares

Remdesivir use in COVID-19 patients might predispose bacteremia, matched case-control analysis
por: Lucijanic, Marko, et al.
Publicado: (2022)

Real-life experience with remdesivir for treatment of hospitalized coronavirus disease 2019 patients: matched case-control study from a large tertiary hospital registry
por: Lucijanić, Marko, et al.
Publicado: (2022)

Remdesivir-associated bradycardia might be a sign of good prognosis in COVID-19 patients
por: Lucijanic, Marko, et al.
Publicado: (2022)

Risks associated with prior oral anticoagulation use in hospitalized COVID-19 patients – A retrospective cohort study on 5392 patients from a tertiary centre
por: Bistrovic, Petra, et al.
Publicado: (2023)

Pharmacists’ interventions improve health-related quality of life of rural older person on warfarin: a randomized controlled trial
por: Falamić, Slaven, et al.
Publicado: (2021)

Remdesivir use in severe and critical COVID-19 patients might be associated with lower incidence of arterial thrombotic events
por: Lucijanic, Marko, et al.
Publicado: (2023)

P1563: REMDESIVIR USE IN SEVERE AND CRITICAL COVID-19 PATIENTS MIGHT BE ASSOCIATED WITH LOWER INCIDENCE OF ARTERIAL THROMBOTIC EVENTS
por: Lucijanic, Marko, et al.
Publicado: (2023)

ECG characteristics associated with adverse outcomes in COVID-19, a tertiary centre experience
por: Bistrovic, P, et al.
Publicado: (2023)

Relative tachycardia at admission as a predictor of mortality in severe and critical COVID-19, a tertiary centre study
por: Bistrovic, P, et al.
Publicado: (2023)

Development and Validation of Comprehensive Healthcare Providers’ Opinions, Preferences, and Attitudes towards Deprescribing (CHOPPED Questionnaire)
por: Bužančić, Iva, et al.
Publicado: (2022)

Differences in Factors Influencing Deprescribing between Primary Care Providers: Cross-Sectional Study
por: Bužančić, Iva, et al.
Publicado: (2023)

Atrial appendages’ mechanics assessed by 3D transoesophageal echocardiography as predictors of atrial fibrillation recurrence after pulmonary vein isolation
por: Zeljković, Ivan, et al.
Publicado: (2020)

PB2220: ATRIAL FIBRILLATION IS FREQUENT IN PATIENTS WITH MYELOFIBROSIS AND MIGHT BE SUB-OPTIMALLY TREATED
por: Lucijanic, Marko, et al.
Publicado: (2023)

Clinical and prognostic significance of C-reactive protein to albumin ratio in hospitalized coronavirus disease 2019 (COVID-19) patients: Data on 2309 patients from a tertiary center and validation in an independent cohort
por: Lucijanić, Marko, et al.
Publicado: (2022)

Incidence and predictors of asymptomatic atrial fibrillation in patients older than 70 years with complete atrioventricular block and dual chamber pacemaker implantation
por: Radeljić, Vjekoslav, et al.
Publicado: (2011)

A Need for Benzodiazepine Deprescribing in the COVID-19 Pandemic: A Cohort Study
por: Bužančić, Iva, et al.
Publicado: (2022)

Patterns of anticoagulation therapy in atrial fibrillation: results from a large real-life single-center registry
por: Jurin, Ivana, et al.
Publicado: (2020)

Role of empirical isolation of the superior vena cava in patients with recurrence of atrial fibrillation after pulmonary vein isolation—a multi-center analysis
por: Knecht, Sven, et al.
Publicado: (2022)

Pharmacists’ role, work practices, and safety measures against COVID-19: A comparative study
por: Novak, Helena, et al.
Publicado: (2021)

Atrial fibrillation‐related stroke in women: Evidence and inequalities in epidemiology, mechanisms, clinical presentation, and management
por: Kostopoulou, Anna, et al.
Publicado: (2019)

Competency (and Beyond): Think Patient. Collaborate. Develop. Evaluate. Improve. Repeat.
por: Bruno-Tomé, Andreia, et al.
Publicado: (2019)

When and which patients should receive remdesivir?
por: Garcia-Vidal, Carolina, et al.
Publicado: (2022)

Treatment implications of renal disease in patients with atrial fibrillation: The BALKAN‐AF survey
por: Kozieł, Monika, et al.
Publicado: (2020)

Identifying self-assessed competencies and areas for improvement within community pharmacist-preceptors support during pre-registration training
por: Držaić, Margita, et al.
Publicado: (2018)

Management of patients with newly-diagnosed atrial fibrillation: Insights from the BALKAN-AF survey
por: Kozieł, Monika, et al.
Publicado: (2019)

Exploring Patients’ Attitudes Toward Deprescribing and Their Perception of Pharmacist Involvement in a European Country: A Cross-Sectional Study
por: Bužančić, Iva, et al.
Publicado: (2021)

Stroke rates before and after ablation of atrial fibrillation and in propensity-matched controls in the UK
por: Jarman, Julian WE, et al.
Publicado: (2017)

Incidence of Osteoporosis in Primary Care Patients with Atrial Fibrillation Receiving Different Oral Anticoagulants
por: Bezabhe, Woldesellassie M., et al.
Publicado: (2022)

Delayed radiofrequency ablation efficacy in slow pathway ablation: a case report
por: Zeljković, Ivan, et al.
Publicado: (2021)

Initiation of Guideline-Matched Oral Anticoagulant in Atrial Fibrillation-Related Stroke
por: Eun, Mi-Yeon, et al.
Publicado: (2021)

Factors That Determine the Prothrombin Time in Patients With Atrial Fibrillation Receiving Rivaroxaban
por: Huang, Jen-Hung, et al.
Publicado: (2018)

Biological Variation in Rotational Thromboelastometry in Patients with Atrial Fibrillation Receiving Rivaroxaban
por: Božič Mijovski, Mojca, et al.
Publicado: (2022)

Stroke prevention in atrial fibrillation and ‘real world’ adherence to guidelines in the Balkan Region: The BALKAN-AF Survey
por: Potpara, Tatjana S., et al.
Publicado: (2016)

Catheter ablation of atrial fibrillation in patients with autoimmune disease: A propensity score matching study based on the China Atrial Fibrillation Registry
por: Gao, Ming‐Yang, et al.
Publicado: (2023)

Duffy‐null erythrocyte phenotype and the risk of thrombotic events in essential thrombocythemia
por: Krecak, Ivan, et al.
Publicado: (2023)

Anticoagulation Control in Different Ethnic Groups Receiving Vitamin K Antagonist for Stroke Prevention in Atrial Fibrillation
por: Zawawi, Nur Azyyati, et al.
Publicado: (2021)

Anticoagulation Control in Older Atrial Fibrillation Patients Receiving Vitamin K Antagonist Therapy for Stroke Prevention
por: Zulkifly, Hanis, et al.
Publicado: (2022)

The Patterns of Non-vitamin K Antagonist Oral Anticoagulants (NOACs) Use in Patients with Atrial Fibrillation in Seven Balkan Countries: a Report from the BALKAN-AF Survey
por: Potpara, Tatjana S., et al.
Publicado: (2017)

Cardiac rehabilitation for heart failure and atrial fibrillation: a propensity- matched study
por: Alhotye, Munyra, et al.
Publicado: (2023)

Use of simplified HAS‐BLED score in patients with atrial fibrillation receiving warfarin
por: Methavigul, Komsing, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_doamg6ar1bkm4fioo0qgdnkq31